On April 4, 2024 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported that management will participate in the following investor conferences in April (Press release, Immunocore, APR 4, 2024, View Source [SID1234641781]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Needham Virtual Healthcare Conference
Fireside Chat: Wednesday, April 10, 2024, at 11:00 a.m. EDT
Canaccord Horizons in Oncology
Panel: T-Cell Engagers for Solid Tumors: Monday, April 15, 2024, at 4:00 p.m. EDT
Kempen Life Sciences Conference
1×1 and small group meetings: Tuesday, April 16, 2024
Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.